Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TScan Therapeutics (TCRX) Net Cash Flow (2020 - 2025)

TScan Therapeutics (TCRX) has disclosed Net Cash Flow for 6 consecutive years, with -$17.1 million as the latest value for Q4 2025.

  • Quarterly Net Cash Flow fell 137.52% to -$17.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$26.3 million through Dec 2025, down 157.98% year-over-year, with the annual reading at -$26.3 million for FY2025, 157.98% down from the prior year.
  • Net Cash Flow for Q4 2025 was -$17.1 million at TScan Therapeutics, down from $112000.0 in the prior quarter.
  • The five-year high for Net Cash Flow was $101.6 million in Q2 2024, with the low at -$109.0 million in Q3 2024.
  • Average Net Cash Flow over 5 years is -$681250.0, with a median of -$15.9 million recorded in 2021.
  • The sharpest move saw Net Cash Flow skyrocketed 1167.38% in 2021, then crashed 558.42% in 2023.
  • Over 5 years, Net Cash Flow stood at -$16.5 million in 2021, then decreased by 4.91% to -$17.3 million in 2022, then fell by 26.36% to -$21.8 million in 2023, then skyrocketed by 308.72% to $45.6 million in 2024, then tumbled by 137.52% to -$17.1 million in 2025.
  • According to Business Quant data, Net Cash Flow over the past three periods came in at -$17.1 million, $112000.0, and $15.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.